<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2412">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723707</url>
  </required_header>
  <id_info>
    <org_study_id>s18-01166</org_study_id>
    <secondary_id>1R21AG057291-01</secondary_id>
    <nct_id>NCT03723707</nct_id>
  </id_info>
  <brief_title>Enhanced Quality in Primary Care for Elders With Diabetes and Dementia</brief_title>
  <acronym>EQUIPED-ADRD</acronym>
  <official_title>Enhanced Quality in Primary Care for Elders With Diabetes and Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and test a care quality improvement intervention&#xD;
      featuring use of consensus decisional guidance for the medical management of diabetes (DM) in&#xD;
      patients with Alzheimer's disease and related dementia (ADRD) in primary care, provider (PCP)&#xD;
      workflow enhancements supported by a panel manager(PM) for workflow support, electronic&#xD;
      health record (EHR) decision support and feedback, and PCP collaborative learning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Intervention patients reaching consensus target HbA1c</measure>
    <time_frame>30 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Control patients reaching consensus target HbA1c</measure>
    <time_frame>30 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diabetes</condition>
  <condition>Dementia</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Intervention (INT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (CON)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EQUIPED-ADRD Intervention</intervention_name>
    <description>(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)</description>
    <arm_group_label>Intervention (INT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control (CON)</intervention_name>
    <description>Will use current guidelines for primary care treatment with Diabetes and Dementia</description>
    <arm_group_label>Control (CON)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must receive care at participating NYU FGP clinics.&#xD;
&#xD;
          -  Patient must be English or Spanish speaking.&#xD;
&#xD;
          -  Patient must have DM diagnosis.&#xD;
&#xD;
          -  Patient must have documented cognitive impairment or an ADRD diagnosis.&#xD;
&#xD;
          -  Patient must have someone who is identified as a family or friend who provides&#xD;
             caregiving assistance.&#xD;
&#xD;
        Caregiver:&#xD;
&#xD;
          -  Caregiver must have adequate knowledge of identified patient and/or participate in&#xD;
             that member's healthcare decisions.&#xD;
&#xD;
          -  Caregiver must be English or Spanish speaking.&#xD;
&#xD;
          -  Caregiver must demonstrate capacity to consent to research participation.&#xD;
&#xD;
          -  Caregiver must be at least 21 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient:&#xD;
&#xD;
          -  Patient does not receive care at participating NYU FGP clinics.&#xD;
&#xD;
          -  Patient is not 65 years and older.&#xD;
&#xD;
          -  Patient is not English or Spanish speaking.&#xD;
&#xD;
          -  Patient does not have DM diagnosis.&#xD;
&#xD;
          -  Patient does not have documented Cognitive impairment or an ADRD diagnosis.&#xD;
&#xD;
          -  Patient has severe dementia, other terminal illness with &lt;6 months to live, and/or is&#xD;
             hospice eligible.&#xD;
&#xD;
          -  Patient does not have a caregiver.&#xD;
&#xD;
        Caregiver:&#xD;
&#xD;
          -  Caregiver does not have adequate knowledge of identified patient and/or does not&#xD;
             participate in that member's healthcare decisions.&#xD;
&#xD;
          -  Caregiver is not English or Spanish speaking.&#xD;
&#xD;
          -  Caregiver lacks capacity to consent to research.&#xD;
&#xD;
          -  Caregiver is under 21 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Chodosh, MD, MSHS, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauricio Arcila-Mesa</last_name>
    <phone>646-501-4660</phone>
    <email>Mauricio.arcila-mesa@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Arcila-Mesa</last_name>
      <phone>646-501-4660</phone>
      <email>Mauricio.arcila-mesa@nyulangone.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>June 20, 2022</last_update_submitted>
  <last_update_submitted_qc>June 20, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification and publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

